For people with T2D that continue to have an HbA1c above target, despite the use of basal insulin, therapy advancement with the addition of a glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) or prandial insulin may be recommended, in particular to improve postprandial glucose (PPG) control.4, 5. This evidence concerns the gene INS and type 2 diabetes mellitus.